Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Molecular Cancer Year : 2014

Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization


Background: The lastly identified claudin-low (CL) subtype of breast cancer (BC) remains poorly described as compared to the other molecular subtypes. We provide a comprehensive characterization of the largest series of CL samples reported so far. Methods: From a data set of 5447 invasive BC profiled using DNA microarrays, we identified 673 CL samples (12,4%) that we describe comparatively to the other molecular subtypes at several levels: clinicopathological, genomic, transcriptional, survival, and response to chemotherapy. Results: CL samples display profiles different from other subtypes. For example, they differ from basal tumors regarding the hormone receptor status, with a lower frequency of triple negative (TN) tumors (52% vs 76% for basal cases). Like basal tumors, they show high genomic instability with many gains and losses. At the transcriptional level, CL tumors are the most undifferentiated tumors along the mammary epithelial hierarchy. Compared to basal tumors, they show enrichment for epithelial-to-mesenchymal transition markers, immune response genes, and cancer stem cell–like features, and higher activity of estrogen receptor (ER), progesterone receptor (PR), EGFR, SRC and TGFβ pathways, but lower activity of MYC and PI3K pathways. The 5-year disease-free survival of CL cases (67%) and the rate of pathological complete response (pCR) to primary chemotherapy (32%) are close to those of poor-prognosis and good responder subtypes (basal and ERBB2-enriched). However, the prognostic features of CL tumors are closer to those observed in the whole BC series and in the luminal A subtype, including proliferation-related gene expression signatures (GES). Immunity-related GES valuable in basal breast cancers are not significant in CL tumors. By contrast, the GES predictive for pCR in CL tumors resemble more to those of basal and HER2-enriched tumors than to those of luminal A tumors. Conclusions: Many differences exist between CL and the other subtypes, notably basal. An unexpected finding concerns the relatively high numbers of ER-positive and non-TN tumors within CL subtype, suggesting a larger heterogeneity than in basal and luminal A subtypes.
Fichier principal
Vignette du fichier
1476-4598-13-228.pdf (1.15 Mo) Télécharger le fichier
Origin : Publisher files allowed on an open archive

Dates and versions

inserm-01192813 , version 1 (03-09-2015)



Renaud Sabatier, Pascal Finetti, Arnaud Guille, José Adelaïde, Max Chaffanet, et al.. Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization. Molecular Cancer, 2014, 13, pp.228. ⟨10.2174/156652412798376134⟩. ⟨inserm-01192813⟩
240 View
146 Download



Gmail Facebook X LinkedIn More